ABC | Volume 111, Nº3, Setembro 2018

Diretrizes Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda Arq Bras Cardiol. 2018; 111(3):436-539 39. Cleland JG, Taylor J, Freemantle N, Goode KM, Rigby AS, Tendera M. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. Eur J Heart Fail. 2012;14(5):487-94. 40. Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail. 2011;4(5):569-77. 41. Ewald B, Ewald D, Thakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J. 2008;38(2):101-13. 42. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807-16. 43. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29(2):270-6. 44. Sahan E, Sahan S, KaramanliogluM, Gul M, TufekciogluO. TheMOGE(S) classification: A TNM-like classification for cardiomyopathies. Herz. 2016;41(6):503-6. 45. Delepaul B, Robin G, Delmas C, Moine T, Blanc A, Fournier P, et al. Who are patients classifiedwithin the new terminology of heart failure from the 20ESC guidelines? ESC Heart Fail. 2017;4(2):99-104. 46. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(12):1574-85. 47. Fang JC, Ewald GA, Allen LA, Butler J, Westlake Canary CA, Colvin-Adams M,etal.Advanced(stageD)heartfailure:astatementfromtheHeartFailure Society of AmericaGuidelines Committee.J Card Fail. 2015;21(6):519-34. 48. Raphael C, Briscoe C, Davies J, Ian Whinnett Z, Manisty C, Sutton R, et al. Limitations of the New York Heart Association functional classification systemand self-reportedwalking distances in chronic heart failure. Heart. 2007;93(4):476-8. 49. van den Broek SA, van VeldhuisenDJ, deGraeff PA, LandsmanML, Hillege H, Lie KI. Comparison betweenNew York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 19921;70(3):359-60. 50. Yancy CW, Januzzi JL Jr., Allen LA, Butler J, Davis LL, Fonarow GC, et al. 2017 ACC Expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018 16;71(2):201-30. 51. JoyceE.Frailtyinadvancedheartfailure.HeartFailClin.2016;12(3):363-74. 52. Springer J, Springer JI, Anker SD. Muscle wasting and sarcopenia in heart failure and beyond: update 2017. ESC Heart Fail. 2017;4(4):492-98. 53. Forman DE, Fleg JL, Kitzman DW, Brawner CA, Swank AM, McKelvie RS, et al. 6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in ambulatory outpatients with systolic heart failure. J Am Coll Cardiol. 2012;60(25):2653-6. 54. Cahalin LP, Chase P, Arena R, Myers J, Bensimhon D, Peberdy MA, et al. A meta-analysis of the prognostic significance of cardiopulmonary exercise testing in patients with heart failure. Heart Fail Rev. 2013;18(1):79-94. 55. Aaronson KD, Schwartz JS, Chen TM, Wong Kl, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95(12):2660-7. 56. LevyWC, MozaffarianD, Linker DT, Sutradhar SC, Anker SD, CroppAB, et al. The Seattle Heart FailureModel: prediction of survival in heart failure. Circulation. 2006;113(11):1424-33. 57. Freitas P, Aguiar C, Ferreira A, Tralhão A, Ventosa A, Mendes M. Comparative Analysis of Four Scores to Stratify PatientsWithHeart Failure and Reduced Ejection Fraction. Am J Cardiol. 2017;120(3):443-9. 58. Agostoni P, Corrà U, Cattadori G, Veglia F, La Gioia R, Scardovi AB, et al. Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: a multiparametric approach to heart failure prognosis. Int J Cardiol. 2013;167(6):2710-8. 59. Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Køber L, Squire IB, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies.Eur Heart J. 2013;34(19):1404-13. 60. Bocchi EA, Bestetti RB, Scanavacca MI, Cunha-Neto E, Issa VS. Chronic Chagas heart disease management: from etiology to cardiomyopathy treatment. J Am Coll Cardiol. 2017;70(12):1510-24. 61. Terhoch CB, Moreira HF, Ayub-Ferreira SM, Conceição-Souza GE, Salemi VMC, Chizzola PR, et al. Clinical findings and prognosis of patients hospitalized for acute decompensated haert failure: Analysis of the influence of Chagas etiology and ventricular function. PLoS Negl TropDis. 2018;12(2):e0006207. 62. Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deciency. N Engl J Med. 2009;361(25):2436-48. 63. Strauss DG, Cardoso S, Lima JA, Rochitte CE, Wu KC. ECG scar quantification correlates with cardiac magnetic resonance scar size and prognostic factors in Chagas’ disease. Heart. 2011;97(5):357-61. 64. Rassi A Jr, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med. 2006;355(8):799-808. 65. Gervais R, Leclercq C, Shankar A, Jacobs S, Eiskjaer H, Johannessen A, et al. Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a sub-analysis of the CARE-HF trial. Eur J Heart Fail. 2009;11(7):699–705. 66. Thomas JT, Kelly RF, Thomas SJ, Stamos TD, Albasha K, Parrillo JE, et al. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. Am J Med. 2002;112(6):437–45. 67. Francis CM, Caruana L, Kearney P, Love M, Sutherland GR, Starkey IR, et al. Open access echocardiographyin management of heart failure in the community. BMJ. 1995;310(6980):634–6. 68. Grayburn PA, Appleton CP, DeMaria AN, Greenberg B, Lowes B, Oh J, et al. Echocardiographicpredictors of morbidity and mortality in patients with advanced heartfailure: the Beta-blocker Evaluation of Survival Trial (BEST). J Am Coll Cardiol. 2005;45(7):1064–71. 69. Douglas PS, Garcia MJ, Haines DE, Lai WW, Manning WJ, Patel AR, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate use criteriafor echocardiography: a report of the American College ofCardiology Foundation Appropriate Use Criteria Task Force, AmericanSociety of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society ofAmerica, Heart Rhythm Society, Society for Cardiovascular Angiographyand Interventions, Society of Critical CareMedicine, Societyof Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2011;57(9):1126-66. 518